Evidence map›Paper›PMID 37943046›Full record

ArticleJournal of virology2023

The effect of single mutations in Zika virus envelope on escape from broadly neutralizing antibodies.

Caroline Kikawa, Catiana H Cartwright-Acar, Jackson B Stuart, Maya Contreras, Lisa M Levoir, Matthew J Evans, Jesse D Bloom, Leslie Goo

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Zika virus: an overview update.Current opinion in HIV and AIDS · 2025
    Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Caroline KikawaDepartment of Genome Sciences, University of Washington , Seattle, Washington, USA.ORCID 0000-0002-8654-5663
Catiana H Cartwright-AcarVaccine and Infectious Disease Division, Fred Hutch Cancer Center , Seattle, Washington, USA.ORCID 0000-0002-2682-0328
Jackson B StuartVaccine and Infectious Disease Division, Fred Hutch Cancer Center , Seattle, Washington, USA.
Maya ContrerasVaccine and Infectious Disease Division, Fred Hutch Cancer Center , Seattle, Washington, USA.ORCID 0009-0004-4212-4471
Lisa M LevoirVaccine and Infectious Disease Division, Fred Hutch Cancer Center , Seattle, Washington, USA.
Matthew J EvansDepartment of Microbiology, Icahn School of Medicine at Mount Sinai , New York, New York, USA.
Jesse D BloomDepartment of Genome Sciences, University of Washington , Seattle, Washington, USA.ORCID 0000-0003-1267-3408
Leslie GooVaccine and Infectious Disease Division, Fred Hutch Cancer Center , Seattle, Washington, USA.ORCID 0000-0002-3866-6735
Fred Hutch Cancer Center · USHoward Hughes Medical Institute · USIcahn School of Medicine at Mount Sinai · USUniversity of Washington · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
Diseases of Public Health Importance Training GrantT32AI007509 · NIAID · UNIVERSITY OF WASHINGTON · PI LUND, JENNIFER M · 1997 to 2024
$6.3M
Viral Pathogenesis Training ProgramT32AI083203 · NIAID · UNIVERSITY OF WASHINGTON · PI BLOOM, JESSE D, LAGUNOFF, MICHAEL · 2009 to 2023
$2.7M
Prospectively characterizing the functional and antigenic effects of mutations to viral entry proteinsR01AI141707 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BLOOM, JESSE D · 2018 to 2022
$2.1M
High-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases ResearchS10OD028685 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2020 to 2020
$2.0M
FHCRC High-Performance Computing ClusterS10OD020069 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KOOPERBERG, CHARLES L · 2015 to 2015
$600k
Howard Hughes Medical InstituteNCI NIH HHS P30 CA015704NIAID NIH HHS R01 AI141707NIAID NIH HHS T32 AI007509NIAID NIH HHS T32 AI083203NIH HHS S10 OD020069NIH HHS S10 OD028685
6 · The paper itself

Abstract

importanceThe wide endemic range of mosquito-vectored flaviviruses-such as Zika virus and dengue virus serotypes 1-4-places hundreds of millions of people at risk of infection every year. Despite this, there are no widely available vaccines, and treatment of severe cases is limited to supportive care. An avenue toward development of more widely applicable vaccines and targeted therapies is the characterization of monoclonal antibodies that broadly neutralize all these viruses. Here, we measure how single amino acid mutations in viral envelope protein affect neutralizing antibodies with both broad and narrow specificities. We find that broadly neutralizing antibodies with potential as vaccine prototypes or biological therapeutics are quantifiably more difficult to escape than narrow, virus-specific neutralizing antibodies.

Indexed as

Antibodies, ViralBroadly Neutralizing AntibodiesViral Envelope ProteinsZika VirusZika Virus InfectionAnimalsCross ReactionsHumansMutationVaccinesViral EnvelopeAntibodies, ViralBroadly Neutralizing AntibodiesVaccinesViral Envelope Proteinsbroadly neutralizing antibodiesdeep mutational scanningdengueZika

Identifiers

PMID37943046
PMCPMC10688354
OpenAlexW4388539873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.